Suppression of human colorectal mucosal prostaglandins: Determining the lowest effective aspirin dose

Journal of the National Cancer Institute

Volumn 89, Issue 15, 1997, Pages 1152-1160

  Ruffin IV, Mack T ^a   Krishnan, Koyamangalath ^b   Rock, Cheryl L ^c   Normolle, Daniel ^a   Vaerten, Mary Ann ^a   Peters Golden, Marc ^a   Crowell, James ^d   Kelloff, Gary ^d   Boland, C Richard ^c   Brenner, Dean E ^a,e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b East Tennessee State University   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; SALICYLIC ACID;

ADULT; ANUS FISSURE; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PROSTAGLANDIN SYNTHESIS; RECTUM HEMORRHAGE;

EID: 0030851487     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.15.1152     Document Type: Article

References (60)

1. Craven PA, DeRubertis FR. Effects of aspirin on 1,2-dimethylhydrazine-induced colonic carcinogenesis. Carcinogenesis 1992;13:541-6.
2. Davis AE, Patterson F. Aspirin reduces the incidence of colonic carcinoma in the dimethylhydrazine rat animal model. Aust N Z J Med 1994;24:301-3.
3. Mereto E, Frencia L, Ghia M. Effect of aspirin on incidence and growth of aberrant crypt foci induced in the rat colon by 1,2-dimethylhydrazine. Cancer Lett 1994;76:5-9.
4. Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ. A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol 1988; 156:341-7.
5. Narisawa T, Sato M, Tani M, Kudo T, Takahashi T, Goto A. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 1981;41: 1954-7.
6. Narisawa T, Hermanek P, Habs M, Schmahl D. Reduction of carcinogenicity of N-nitrosomethylurea by indomethacin and failure of resuming effect of prostaglandin E2 (PGE2) against indomethacin. J Cancer Res Clin Oncol 1984;108:239-42.
7. Pollard M, Luckert PH. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981;214:558-9.
8. Pollard M, Luckert PH, Schmidt MA. The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett 1983; 21:57-61.
9. Pollard M, Luckert PH. Prevention and treatment of primary intestinal tumors in rats by piroxicam. Cancer Res 1989;49:6471-3.
10. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987;47: 5340-6.
11. Reddy BS, Ruo CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993;14:1493-7.
12. Reddy BS, Rao CV, Rivenson A. Aspirin inhibits colon carcinogenesis in F344 rats [abstract]. Proc Am Assoc Cancer Res 1993;34: A3319.
13. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE. NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993;88: 1652-6.
14. Shiff SJ, Qiao L, Tsai LL, Arvind P, Rigas B. Aspirin and aspirin-like drugs alter the growth rate and cell cycle distribution of HT29 colon cancer cells [abstract]. Proc Am Assoc Cancer Res 1994;35:A3765.
15. Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut 1987;28:315-8.
16. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993;122:518-23.
17. Isomaki HA, Hakulinen T, Joutsenlahti V. Excess risk of lymphomas, leukemia, and myeloma in patient with rheumatoid arthritis. J Chronic Dis 1978;31:691-6.
18. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355-8.
19. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399-404.
20. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
21. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
22. Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285-9.
23. Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993;85:912-6.
24. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 1993;85:307-11.
25. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer 1994;74:1847-54.
26. Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994;154:394-9.
27. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
28. Martinez ME, McPherson RS, Levin B, Annegers JF. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev 1995;4:703-7.
29. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic disease: a cohort study of the elderly. BMJ 1989;299: 1247-50.
30. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1220-4.
31. Plescia OJ, Grinwich K, Plescia AM. Subversive activity of syngeneic tumor cells as an escape mechanism from immune surveillance and the role of prostaglandins. Ann N Y Acad Sci 1976;276:455-65.
32. Lynch NR, Castes M, Astoin M, Salomon JC. Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br J Cancer 1978; 38:503-12.
33. Craven PA, DeRubertis FR. Profiles of eicosanoid production by superficial and proliferative colonic epithelial cells and sub-epithelial colonic tissue. Prostaglandins 1986;32:387-99.
34. Craven PA, Patterson MC, DeRubertis FR. Role of enhanced arachidonate availability through phospholipase A2 pathway in mediation of increased prostaglandin synthesis by glomeruli from diabetic rats. Diabetes 1988;37: 429-35.
35. Craven PA, Thornburg K, DeRubertis FR. Sustained increase in the proliferation of rat colonic mucosa during chronic treatment with aspirin. Gastroenterology 1988;94:567-75.
36. DeRubertis FR, Craven PA. Early alterations in rat colonic mucosal cyclic nucleotide metabolism and protein kinase activity induced by 1,2-dimethylhydrazine. Cancer Res 1980;40: 4589-98.
37. Craven PA, Saito R, DeRubertis FR. Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest 1983;72:1365-75.
38. Earnest D, Hixson L, Finely PR, Blackwell G, Einspahr J, Emerson S, et al. Arachidonic acid cascade inhibitors in chemoprevention of human colonic cancer: preliminary studies. In: Wattenberg L, Lipkin M, Boone C, Kelloff G, editors. Cancer chemoprevention. Boca Raton (FL): CRC Press, 1992:165-80.
39. Narisawa T, Kusaka H, Yamazaki Y, Takahashi M, Koyama H, Koyama K, et al. Relationship between blood plasma prostaglandin E2 and liver and lung metastases in colorectal cancer. Dis Colon Rectum 1990;33: 840-5.
40. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
41. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
42. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
43. Costa A, Malone W, Perloff M, Buranelli F, Campa T, Dossena G, et al. Tolerability of the synthetic retinoid Fenretinide (HPR). Eur J Cancer Clin Oncol 1989;25:805-8.
44. Bevitt RN, Mather JR, Sharman DC. Minimization of salicylic acid formation during preparation of aspirin products for analysis by high-performance liquid chromatography. Analyst 1984;109:1327-9.
45. Buskin JN, Upton RA, Williams RL. Improved liquid-chromatography of aspirin, salicylate, and salicyluric acid in plasma, with a modification for determining aspirin metabolites in urine. Clin Chem 1982;28:1200-3.
46. Burney KD, Krishnan K, Ruffin MT, Zhang D, Brenner DE. Adherence to single daily dose of aspirin in a chemoprevention trial. An evaluation of self-report and microelectronic monitoring. Arch Fam Med 1996;5:297-300.
47. Rowland M, Tozer T. Clinical pharmacokinetics. 2nd ed. Philadelphia: Lea & Febiger, 1989.
48. Williams DA. A test for differences between treatment means when several dose levels are compared with a zero dose control. Biometrics 1971;27:103-17.
49. Williams DA. The comparison of several dose levels with a zero dose control. Biometrics 1972;28:519-31.
50. Charman W, Kerins D, Fitzgerald G. Aspirin: pharmacokinetics and pharmacodynamic effects on platelets and vascular function. In: Vane J, Botting R, editors. Aspirin and other salicylates. New York: Chapman & Hall Medical, 1992:74-106.
51. Janssen PL, Hollman PC, Reichman E, Venema DP, van Staveren WA, Katan MB. Urinary salicylate excretion in subjects eating a variety of diets shows that amounts of bioavailable salicylates in food are low. Am J Clin Nutr 1996;64:743-7.
52. Swain AR, Dutton SP, Truswell AS. Salicylates in foods. J Am Diet Assoc 1985;85:950-60.
53. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991;114:835-9.
54. Verheugt FW, van der Laarse A, Funke-Kupper AJ, Sterkman LG, Galema TW, Roos JP. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. Am J Cardiol 1990;66: 267-70.
55. Manson JE, Grobbee DE, Stampfer MJ, Taylor JO, Goldhaber SZ, Gaziano JM, et al. Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians. Am J Med 1990;89:772-6.
56. Forster W, Hoffmann W. Superior prevention of reinfarction by 30 mg/d aspirin compared with 1000 mg/d: results of a two years follow-up study in Cottbus. Biomed Biochim Acta 1988;47:S248-51.
57. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996;56:733-7.
58. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong W. Biomarkers as intermediate end point in chemoprevention trials. J Natl Cancer Inst 1990;82:555-60.
59. Finley PR, Bogert CL, Alberts DS, Einspahr J, Earnest DL, Blackwell G, et al. Measurement of prostaglandin E2 in rectal mucosa in human subjects: a method study. Cancer Epidemiol Biomarkers Prev 1995;4:239-44.
60. Kelloff GJ, Crowell JA, Boone CW, Steele VE, Lubet RA, Greenwald P, et al. Clinical development plan: aspirin. J Cell Biochem Suppl 1994;20:74-85.